Citations

Clear

22 citation(s) found for "Johnson, Amanda".

Reviewing the impact of obesity on inflammatory bowel disease and considerations for optimizing management
Johnson, Amanda M. , Ghusn, Wissam , Loftus, Edward V.

Mayo Clinic

Current Opinion in Gastroenterology | April 25, 2024 | Volume: 40 | Issue: 4 | Pages: 268-275

10.1097/mog.0000000000001025 | PMID 38662340 Get It

Purpose of review This review examines the complex relationship between obesity and inflammatory bowel disease (IBD), encompassing their potentially shared pathogenesis, the impact of obesity on the natural history and treatment outcomes of IBD, and the management of obesity in the patient with IBD. Recent findings Obesity represents a state of chronic inflammation that may not only contribute to IBD pathogenesis, but also influence disease progression, complications, and response to treatment. Increased visceral adiposity may carry negative prognostic implications for disease and treatment-specific outcomes. Antiobesity medications, endoscopic bariatric therapies, and even bariatric surgery may be effective and well tolerated in selected patients with IBD. Summary The intersection of obesity and IBD presents a significant clinical challenge, with obesity influencing the natural history of IBD and potentially affecting treatment efficacy. As obesity prevalence among IBD patients rises, a tailored approach to management is crucial, taking into account the individualized risks and benefits of various treatment strategies, including lifestyle interventions, pharmacotherapy, endoscopic procedures, and bariatric surgery.
Real-World Effectiveness of Ustekinumab in Ulcerative Colitis in a United States Multicenter Cohort Consortium
Yarur, Andrés , Ungaro, Ryan C. , Huang, Katherine , Wang, Wenfei , Sasankan, Priya , Zulqarnain, Mir, Johnson, Amanda M. , Bader, Geoffrey , Kay, Carl , Costable, Nicholas , Dulaney, David , Fenster, Marc, Beniwal‐Patel, Poonam , Syal, Gaurav , Cohen, Benjamin L., Yarur, Andres J , Ungaro, Ryan , Loftus, Edward, Deepak, Parakkal , Patel, Anish A , Loftus, Edward V. , Pekow, Joel , Deepak, Parakkal

Mayo Clinic

Inflammatory Bowel Diseases | March 26, 2024 | Volume: 31 | Issue: 1 | Pages: 131-139

10.1093/ibd/izae058 | PMID 38531068 Get It

Abstract Background Pivotal trials have shown that ustekinumab is effective in ulcerative colitis (UC). However, the population included in these trials do not represent the cohort of patients treated in the real world. In this study, we aimed to describe the effectiveness and safety of ustekinumab in a clinical cohort of patients with UC. Methods We performed a multicenter retrospective cohort study and included patients with active UC starting ustekinumab. Variables collected included demographics, clinical data, and disease activity (measured using partial Mayo score [PMS] and endoscopic Mayo score) at follow-up. The primary outcomes were cumulative rates of steroid-free clinical and biochemical remission (SFCBR), defined as a PMS <2 while off steroids and a normal C-reactive protein and/or fecal calprotectin. Results A total of 245 patients met inclusion criteria. The median time of follow-up was 33 (interquartile range, 17-53) weeks, and 214 (87.3%) had previous exposure to a biologic and/or tofacitinib. Rates of SFCBR, clinical remission, and endoscopic remission at 6 and 12 months were 12.0% (n = 16 of 139), 29.0% (n = 71 of 175), and 18.0% (n = 7 of 39), and 23.8% (n = 15 of 63), 54.3% (n = 57 of 105), and 31.0% (n = 9 of 29), respectively. Non-Hispanic White race, higher baseline PMS, and the use of concomitant corticosteroids were independently associated with failure to achieve SFCBR. Of the 73 that were dose escalated, 28.4% did not respond, 49.3% experienced a benefit, and 21.6% achieved remission. Conclusions In a population enriched with refractory UC, ustekinumab was well tolerated and induced remission in a significant number of patients. Larger studies with a longer follow-up are warranted.
Risankizumab to treat moderately to severely active Crohn’s disease in adults: an evaluation of trials and data
Johnson, Amanda M. , Loftus, Edward V.

Mayo Clinic

Expert Review of Gastroenterology & Hepatology | December 14, 2023 | Volume: 17 | Issue: 12 | Pages: 1169-1183

10.1080/17474124.2023.2295496 | PMID 38095092 Get It

Effectiveness and Safety of Antiobesity Medications in Patients With Obesity and Inflammatory Bowel Disease
Pham, J. , Ghusn, Wissam , Acosta, Andrés , Loftus, Edward V. , Johnson, Amanda M. , Pham, Jonathan T , Ghusn, Wissam , Loftus, Edward V , Acosta, Andres

Mayo Clinic

American Journal of Gastroenterology | October 9, 2023 | Volume: 119 | Issue: 6 | Pages: 1197-1200

10.14309/ajg.0000000000002490 | PMID 37811776 Get It

INTRODUCTION: Limited data exist evaluating antiobesity medications (AOM) in patients with inflammatory bowel disease (IBD). METHODS: We performed a case-control study evaluating the effectiveness and safety of AOM in patients with IBD with obesity, matched to non-IBD controls. RESULTS: After 12 months, the case (n = 36) and control (n = 36) groups achieved similar percent total body weight loss of −6.9 ± 8.3 and −8.1 ± 7.0 ( P = 0.30), respectively. Side effect profiles were similar between groups. Seven patients experienced an IBD flare, all managed medically. DISCUSSION: AOM use in patients with IBD demonstrated similar effectiveness and safety when compared with that observed in the non-IBD population.
Prevalence and Impact of Obesity in a Population-Based Cohort of Patients With Crohn’s Disease
Johnson, Amanda M. , Harmsen, William S. , Tremaine, William J., Raffals, Laura E. , Harmsen, William Scott, Aniwan, Satimai , Dayyeh, Barham K. Abu , Loftus, Edward V.

Mayo Clinic

Journal of Clinical Gastroenterology | February 2, 2023 | Volume: 58 | Issue: 2 | Pages: 176-182

10.1097/mcg.0000000000001821 | PMID 36728679 Get It

Background: Obesity is on the rise within the inflammatory bowel disease population. The impact obesity has on the natural history of Crohn’s disease (CD) is not well-understood. We aimed to describe the prevalence of obesity in a population-based cohort of newly diagnosed patients with CD, and the impact obesity had on disease phenotype and outcomes of corticosteroid use, hospitalization, intestinal resection, and development of fistulizing or penetrating disease. Materials and Methods: A chart review was performed on Olmsted County, Minnesota residents diagnosed with CD between 1970 and 2010. Data were collected on demographics, body mass index, CD location and behavior, CD-related hospitalizations, corticosteroid use, and intestinal resection. The proportion of individuals considered obese at the time of CD diagnosis was evaluated over time, and CD-associated complications were assessed with Kaplan-Meier survival analysis. Results: We identified 334 individuals diagnosed with CD between 1970 and 2010, of whom 156 (46.7%) were either overweight (27.8%) or obese (18.9%) at the time of diagnosis. The proportion of patients considered obese at the time of their diagnosis of CD increased 2-3 fold over the course of the study period. However, obesity did not have a significant impact on the future risk of corticosteroid use, hospitalization, intestinal resection, or development of penetrating and stricturing complications. Conclusions: Obesity is on the rise in patients with CD, although in this cohort, there did not appear to be any negative association with future CD-related outcomes. Further prospective studies, ideally including obesity measures such as visceral adipose tissue assessment, are warranted to understand the implications of the rising prevalence of obesity on CD outcomes.
The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium
Johnson, Amanda M. , Barsky, Maria, Ahmed, Waseem , Zullow, Samantha, Galati, Jonathan S. , Jairath, Vipul , Narula, Neeraj , Peerani, Farhad , Click, Benjamin , Coburn, Elliot, Dang, ThucNhi T. , Garg, Rajat , Aggarwal, Manik , Mohammad, Danah, Halloran, Brendan P. , Kochhar, Gursimran , Todorowski, Hannah, Din, Nabeeha Mohy Ud, Izanec, James , Teeple, Amanda, Gasink, C, Muser, Erik, Ding, Zhijie , Lakhani, Komal, Hogan, Dan, Datta, Samit, Boland, Brigid S. , Bohm, Matthew , Fischer, Monika , Sagi, Sashidhar , Afzali, Anita , Ullman, Thomas, Lawlor, Garrett , Baumgart, Daniel C. , Chang, Shannon, Scherl, Ellen , Sandborn, William J. , Bruining, David H. , Kane, Sunanda V. , Loftus, Edward V. , Dulai, Parambir S. , Jairath, Vipul , Jairath, Vipul , Bruining, David, Jairath, V , Jairath, V , Loftus, Edward V , Jairath, Vipul , Gold, Stephanie Lauren , Agrawal, Manasi , Swaminath, Arun C. , Hogan, Dan, Ungaro, Ryan C. , Chang, Shannon, Hudesman, David , Lukin, Dana J. , Colombel, Jean‐Frédéric , Sands, Bruce E , Siegel, Corey A , Regueiro, Miguel

Mayo Clinic

American Journal of Gastroenterology | October 3, 2022 | Volume: 118 | Issue: 2 | Pages: 317-328

10.14309/ajg.0000000000002047 | PMID 36191274 Get It

INTRODUCTION: We evaluated the real-world effectiveness and safety of ustekinumab (UST) in patients with Crohn's disease (CD). METHODS: This study used a retrospective, multicenter, multinational consortium of UST-treated CD patients. Data included patient demographics, disease phenotype, disease activity, treatment history, and concomitant medications. Cumulative rates of clinical, steroid-free, endoscopic, and radiographic remissions were assessed using time-to-event analysis, and clinical predictors were assessed by using multivariate Cox proportional hazard analyses. Serious infections and adverse events were defined as those requiring hospitalization or treatment discontinuation. RESULTS: A total of 1,113 patients (51.8% female, 90% prior antitumor necrosis factor exposure) were included, with a median follow-up of 386 days. Cumulative rates of clinical, steroid-free, endoscopic, and radiographic remissions at 12 months were 40%, 32%, 39%, and 30%, respectively. Biologic-naive patients achieved significantly higher rates of clinical and endoscopic remissions at 63% and 55%, respectively. On multivariable analyses, prior antitumor necrosis factor (hazard ratio, 0.72; 95% confidence interval, 0.49–0.99) and vedolizumab exposure (hazard ratio, 0.65; 95% confidence interval, 0.48–0.88) were independently associated with lower likelihoods of achieving endoscopic remission. In patients who experienced loss of remission, 77 of 102 (75%) underwent dose optimization, and 44 of 77 (57%) achieved clinical response. An additional 152 of 681 patients (22.3%) were dose-optimized because of primary nonresponse incomplete response to UST, of whom 40.1% (61 of 152) responded. Serious infections occurred in 3.4% of patients while other noninfectious adverse events (lymphoma [n = 1], arthralgia [n = 6], rash [n = 6], headache [n = 3], hepatitis [n = 3], hair loss [n = 3], neuropathy [n = 1], and vasculitis [n = 1]) occurred in 2.4% of patients. DISCUSSION: UST represents a safe and effective treatment option for CD, with 40% of patients from a highly refractory cohort achieving clinical remission by 12 months. The greatest treatment effect of UST was seen in biologic-naive patients, and dose escalation may recapture clinical response.
Patient and Caregiver-Derived Health Service Improvements for Better Critical Care Recovery
Haines, K.J., Leggett, Nina , Hibbert, Elizabeth , Hall, Tarli, Bakhru, Rita N. , Bastin, Anthony J. , Butcher, Brad W. , Harris, Wendy, Hope, Aluko A. , Jackson, J.C., Johnson, Amanda M. , Kloos, Janet A. , Korzick, Karen , MacTavish, Pamela , Montgomery-Yates, Ashley , Slack, Andrew, Still, M. , Netzer, Giora, Hopkins, RO, Sevin, Carla M. , Boehm, Leanne M. , Eaton, Tammy L. , Meyer, Joel , Quasim, Tara , Wade, Dorothy , Mikkelsen, Mark E. , Iwashyna, Theodore J. , McPeake, Joanne

Mayo Clinic

C94. THE ROAD TO RECOVERY TAKES MANY PATHS: OUTCOMES AFTER CRITICAL ILLNESS | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A4787-A4787

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a4787 Get It

Vulvar Crohn's Disease: Clinical Features and Outcomes
Cho, Janice , Loftus, Edward V. , Bruining, David H. , Chedid, Victor , Faubion, William A. , Johnson, Amanda M. , Kane, Sunanda V. , Papadakis, Konstantinos A. , Pardi, Darrell S. , Picco, Michael F., Raffals, Laura E. , Schroeder, Kenneth W., Tremaine, William J., Cho, Janice M, Chedid, Victor G , Loftus, Edward V , Farraye, Francis A. , Kisiel, John B. , Malik, Talha A. , Coelho–Prabhu, Nayantara

Mayo Clinic

American Journal of Gastroenterology | September 9, 2021 | Volume: 116 | Issue: 11 | Pages: 2296-2299

10.14309/ajg.0000000000001502 | PMID 34732676 Get It

INTRODUCTION: Vulvar involvement is a rare complication of Crohn's disease (CD). The optimal treatment of vulvar CD is unknown. METHODS: We conducted a 25-year retrospective cohort study of vulvar CD from 3 referral centers. Clinical features and outcomes were studied. RESULTS: Fifty patients were identified. The most common vulvar symptoms were pain (74%), edema (60%), ulcerations (46%), nodules (36%), and abscess (34%). Medical management leading to symptomatic improvement varied, and 5 patients ultimately required surgery. DISCUSSION: Vulvar CD manifests with a broad spectrum of symptoms. Aggressive medical management was frequently effective, although surgery was required in 10% of cases.
Prevalence and Impact of Obesity on Disease-specific Outcomes in a Population-based Cohort of Patients with Ulcerative Colitis
Johnson, Amanda M. , Harmsen, William S. , Tremaine, William J., Loftus, Edward V. , Aniwan, Satimai , Loftus, Edward V , Dayyeh, Barham K. Abu

Mayo Clinic

Journal of Crohn's and Colitis | June 4, 2021 | Volume: 15 | Issue: 11 | Pages: 1816-1823

10.1093/ecco-jcc/jjab097 | PMID 34117877 Get It

Abstract Background and Aims There remains a historical misconception that inflammatory bowel disease [IBD] patients are underweight. However, recent data suggest rates of obesity in IBD parallel to those of the general population. The impact obesity has on the natural history of IBD is unclear. We aimed to determine obesity rates at the time of IBD diagnosis in a population-based cohort of ulcerative colitis [UC] patients. Methods Chart review was performed on patients diagnosed with UC over 1970–2010. Data were collected on demographics, body mass index [BMI], disease characteristics, IBD-specific hospitalisations, intestinal resection, and corticosteroid use. The proportion of patients who were obese at the time of their diagnosis was evaluated over time, and survival free of IBD-related complications was assessed using Kaplan-Meier survival analysis. Results A total of 417 adults were diagnosed with UC over 1970–2010, 55.4% of whom were classified as either overweight [34.8%] or obese [20.6%]. The prevalence of obesity increased 2–3-fold over the 40-year study period. Obese patients had a 72% increased risk of hospitalisation (hazard ratio [HR],1.72; 95% confidence interval [CI], 1.10–2.71; p = 0.018) when compared with normal weight patients. Additionally, with each incremental increase in BMI by 1 kg/m2, the risk of hospitalisation increased by 5% [HR,1.05; 95% CI, 1.01–1.08; p = 0.008] and risk of corticosteroid use increased by 2.6% [HR,1.026; 95% CI, 1.00–1.05; p = 0.05]. Conclusions The prevalence of obesity in the UC population is increasing and may have negative prognostic implications, specifically regarding risk of future hospitalisation and corticosteroid use. Additional prospective studies are necessary to more clearly define these associations.
P325 Real-World Effectiveness And Safety Of Ustekinumab In Patients With Ulcerative Colitis: A Multi-Centre Study
Parakkal, D, Johnson, Amanda M. , Fenster, Marc, Zulqarnain, Mir, Ullman, Thomas, Gutierrez, A , Bruss, Alexandra, Cohen, Benjamin L., Gaurav, S, Anish, P, Sasankan, Priya , Costable, Nicholas , Wang, W, Ciorba, Matthew A. , Beniwal‐Patel, Poonam , Yarur, Andrés , Yarur, Andres J , Ramos, Guilherme Piovezani , Huang, Laurence , Ungaro, Ryan C. , Gaurav, S, Anish, P, Pekow, Joel , Rubin, David T. , Loftus, Edward V.

Mayo Clinic

Journal of Crohn's and Colitis | May 28, 2021 | Volume: 15 | Issue: Supplement_1 | Pages: S349-S350

10.1093/ecco-jcc/jjab076.449 Get It

Abstract Background Pivotal trials have shown that ustekinumab (UST) is effective in ulcerative colitis (UC). However, the population included in these trials do not always represent the cohort of patients treated in the “real world”. In this study, we aimed to describe the effectiveness and safety of UST in a clinical cohort of patients with UC Methods We performed a multi-center cohort study and included patients with active UC starting UST. Variables collected included demographics, previous and current UC medications, disease activity (measured using partial and endoscopic Mayo score [PMS and EMS]) at 8 weeks, 6 months and end of follow-up. We also abstracted UST drug level and anti-UST antibodies (AUA), albumin and C-reactive protein levels. Primary outcomes were clinical response at week 8 defined as a reduction of 3 points in the PMS or PMS<2. Secondary outcomes were clinical remission defined as a PMS <2 and endoscopic remission defined as a MES ≤1, and the development of an adverse event (AE) attributed to UST. Results Ninety-five patients were included with a median age of 42 years (IQR:32-57) and 53 (56%) were female. Median follow-up was 5 months (IQR:2.2-7.4). Only 4 (4.3%) were naïve to biologics or tofacitinib and 62 (66%) had previous exposure to at least 2 other biologics. No variables were found to be associated with response at week 8 (Figure 2). Those patients who responded at week 8 had higher median albumin levels vs those who did not (median of 4.4 [IQR: 4.1-4.6] vs 4.1 g/dL [IQR:3.8-4.3]; p=0.02). There were no differences in baseline CRP levels (1mg/dL [IQR:0.6-2.8] vs 0.6 mg/dL [0.3-1.5]; p=0.06). Among the 33 patients who had follow-up endoscopic assessment, 7 (21.2%) had achieved endoscopic remission and 4 (12%) achieved histologic remission. Median UST level was 4.1 mcg/ml (IQR:2.5-5.1) and no patients had detectable AUA. Five patients underwent colectomy (5.3%). Only 6 patients (6.6%) presented with an AE (all minor that included, rash, headaches, arthralgias and infection). Conclusion In a population enriched with refractory UC, UST was well tolerated and induce response and remission in a significant number of patients. The rate of response was lower in obese patients and those with extensive colitis but was not associated with previous exposure to biologics and/or tofacitinib. Larger studies with a longer follow-up are warranted. Figure 1: Rates of clinical response and remission in patients with UC receiving ustekinumab Figure 2: Association between several baseline characteristics and response to ustekinumab in UC